Belite Bio (BLTE) said late Wednesday it signed a securities purchase deal with a new healthcare investor to buy and sell 258,309 of its American depositary shares and warrants to buy equal amount of American depositary shares at $58.07 per ADS in a registered direct offering for gross proceeds of roughly $15 million.
The biopharmaceutical company intends to close the offering around Friday, and plans to use the net proceeds for working capital and general corporate purposes, it added.
Belite Bio's stock was down more than 1% in recent Thursday premarket activity.
Price: 57.11, Change: -0.96, Percent Change: -1.65